Kim J H, Ohsawa M
Department of Environmental Toxicology, Faculty of Pharmaceutical Sciences, Teikyo University, Kanagawa, Japan.
Biol Pharm Bull. 1995 Jun;18(6):854-8. doi: 10.1248/bpb.18.854.
Oral tolerance is thought to have a role in preventing allergic responses and immune-mediated diseases. Modulation of this tolerance by drugs and chemicals can cause or suppress them. An improved model of oral tolerance to ovalbumin (OVA) in mice was developed to detect modulators of the tolerance and to apply it to selected immunomodulating substances, cyclophosphamide (CP), Escherichia coli lipopolysaccharide (LPS) and cadmium chloride (Cd). Male C3H/HeN mice given an oral administration of 20 mg OVA were immunized 7 d later with an i.p. injection of 0.1 mg OVA in complete Freund's adjuvant. Effects of oral OVA and agents on systemic immunity were assessed by enzyme-linked immunosorbent assay (ELISA) of immunoglobulin (Ig) levels in serum collected 7 or 14 d after immunization. Oral tolerance was adequately induced on day 7 after immunization and was more effective in C3H/HeN mice than in BALB/c mice. It was primarily associated with the decreased serum levels of anti-OVA IgG (including both IgG1 and IgG2a subclasses regulated differently by T-helper subpopulations, Th2 and Th1 cells, respectively). The C3H model of oral tolerance was further examined to detect modulators of the tolerance. An i.p. injection of CP prior to oral OVA, or 5 consecutive daily oral administrations of LPS after oral OVA elevated or reduced serum levels of anti-OVA IgG in C3H mice hyposensitized by the oral OVA, respectively. Concerning IgG subclasses, CP restored anti-OVA IgG2a but not IgG1 levels, while LPS caused greater suppression of both anti-OVA IgG1 and IgG2a levels. Oral administrations of Cd for 5 d after oral OVA also suppressed anti-OVA IgG1 levels further.(ABSTRACT TRUNCATED AT 250 WORDS)
口服耐受被认为在预防过敏反应和免疫介导疾病中发挥作用。药物和化学物质对这种耐受的调节可引发或抑制这些反应。开发了一种改进的小鼠卵清蛋白(OVA)口服耐受模型,以检测耐受调节剂,并将其应用于选定的免疫调节物质,如环磷酰胺(CP)、大肠杆菌脂多糖(LPS)和氯化镉(Cd)。给雄性C3H/HeN小鼠口服20mg OVA,7天后腹腔注射0.1mg OVA与完全弗氏佐剂进行免疫。通过酶联免疫吸附测定(ELISA)检测免疫后7天或14天收集的血清中免疫球蛋白(Ig)水平,评估口服OVA和试剂对全身免疫的影响。免疫后第7天充分诱导了口服耐受,且在C3H/HeN小鼠中比在BALB/c小鼠中更有效。它主要与抗OVA IgG血清水平降低有关(包括分别由辅助性T细胞亚群Th2和Th1细胞不同调节的IgG1和IgG2a亚类)。进一步研究C3H口服耐受模型以检测耐受调节剂。在口服OVA之前腹腔注射CP,或在口服OVA后连续5天每日口服LPS,分别提高或降低了经口服OVA致敏不足的C3H小鼠中抗OVA IgG的血清水平。关于IgG亚类,CP恢复了抗OVA IgG2a水平,但未恢复IgG1水平,而LPS对抗OVA IgG1和IgG2a水平均有更大程度的抑制。口服OVA后连续5天口服Cd也进一步抑制了抗OVA IgG1水平。(摘要截短至250字)